Treatment with JKE-1674 for 4 weeks significantly inhibited the volume and weight of RB-knockdown PC3 xenografts by 40.6% and 30.3%, respectively (Figure 4, A–C), but had a minor and insignificant antitumor effect in control PC-3 xenografts (Figure 4, A–C), suggesting that RB1 depletion markedly sensitizes prostate tumors to JKE-1674 treatment. This evidence concerns the gene RB1 and prostate neoplasm.